Diabetes mellitus is the main aetiology of end stage kidney disease (ESKD) in Malaysia. However, there may be concerns of over-reporting of diabetes mellitus as the cause of ESKD in the Malaysian Dialysis and Transplant Registry (MDTR). The objective of this audit is to assess the accuracy of data collected in the MDTR. There were 151 centres/source data providers (SDP) with a total of 1977 patients included in this audit. The audit showed that 80.2% of doctors' records matched the MDTR data. The results were comparable with published validation studies in other countries.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Calcific Uremic Arteriolopathy (CUA) Among Malaysian Dialysis Patients: Clinical Characteristics, Treatment, and Outcomes.
Cureus
November 2024
Department of Nephrology, Universiti Malaya Medical Centre, Kuala Lumpur, MYS.
Background Calcific uremic arteriolopathy (CUA) is a rare but debilitating disease affecting patients with kidney disease. Reported risk factors of CUA in the literature include female sex, obesity, diabetes mellitus, and vitamin K antagonists' (VKAs) usage. CUA prevalence in Malaysia is unknown and has not been reported before.
View Article and Find Full Text PDFThe expression profile analysis and functional prediction of lncRNAs in peripheral blood mononuclear cells in maintenance hemodialysis patients developing heart failure.
Sci Rep
November 2024
Department of Clinical Laboratory Medicine, Ziyang Central Hospital, Ziyang, 641300, Sichuan Province, China.
Article Synopsis
- Heart failure (HF) is a major cause of death in patients undergoing maintenance hemodialysis, and this study focuses on the role of long non-coding RNAs (lncRNAs) in diagnosing and assessing HF risk in these patients.
- Researchers analyzed lncRNA expressions in blood samples from hemodialysis patients with different types of HF, discovering 1,429 differentially expressed lncRNAs, with specific candidates suggesting a potential role in disease severity and prognosis.
- One key lncRNA, ENST00000561762, showed a strong correlation with important health indicators like left ventricular ejection fraction and could provide insights into future diagnostic and treatment strategies for heart failure in hemodialysis patients.
Prevalence, Risk Factors, and Management of Metabolic Acidosis in Chronic Kidney Disease Patients: A Multicenter Retrospective Study in Malaysia.
Cureus
March 2024
Department of Nephrology, Hospital Umum Sarawak, Kuching, MYS.
Background Metabolic acidosis in chronic kidney disease (CKD) patients has lately gained attention due to the growing evidence of its treatment benefits. This study aims to provide baseline data on the prevalence, risk factors, and current management of metabolic acidosis among the pre-dialysis adult Malaysian CKD population. Methodology This multicenter cross-sectional retrospective study involved pre-dialysis CKD patients above 18 years old on regular nephrology clinic follow-up at three Malaysian government hospitals with nephrology subspecialty.
View Article and Find Full Text PDFAudit on data accuracy of the Malaysian Dialysis and Transplant Registry (MDTR).
Med J Malaysia
March 2024
National Renal Registry, Malaysia.
Diabetes mellitus is the main aetiology of end stage kidney disease (ESKD) in Malaysia. However, there may be concerns of over-reporting of diabetes mellitus as the cause of ESKD in the Malaysian Dialysis and Transplant Registry (MDTR). The objective of this audit is to assess the accuracy of data collected in the MDTR.
View Article and Find Full Text PDFEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Lancet Diabetes Endocrinol
January 2024
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!